Heather Preston Buys 11,389 Shares of Oxford Biomedica plc (LON:OXB) Stock

Oxford Biomedica plc (LON:OXB - Get Free Report) insider Heather Preston purchased 11,389 shares of the business's stock in a transaction dated Tuesday, June 17th. The shares were purchased at an average price of GBX 324 ($4.40) per share, for a total transaction of £36,900.36 ($50,075.13).

Oxford Biomedica Stock Performance

OXB traded down GBX 4.50 ($0.06) during mid-day trading on Tuesday, reaching GBX 318 ($4.32). 31,308 shares of the company traded hands, compared to its average volume of 256,236. The stock has a market capitalization of £338.04 million, a P/E ratio of -2.36 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. Oxford Biomedica plc has a 52-week low of GBX 232.50 ($3.16) and a 52-week high of GBX 455 ($6.17). The company's fifty day moving average price is GBX 304.26 and its 200-day moving average price is GBX 348.84.

Oxford Biomedica (LON:OXB - Get Free Report) last issued its earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.57)) earnings per share for the quarter. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%. On average, sell-side analysts expect that Oxford Biomedica plc will post -31.0799998 EPS for the current year.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.